Skip to main content

Yancopoulos George's Form 4 filing

Regeneron Pharmaceuticals, Inc. (REGN) · filed Mar 27, 2023

Accession no.
0001883850-23-000062
Filed
Mar 27, 2023
Trade date
Mar 23, 2023
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 8 non-derivative transactions. Open-market sales total $2.94M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Yancopoulos GeorgeCIK 0001226690Director, Officer (President and Chief Scientific)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 23, 2023Common StockSSaleDisposed−254$800.59F2−$203,349.86200,250Indirect
Mar 23, 2023Common StockSSaleDisposed−122$801.16F4−$97,741.52200,128Indirect
Mar 23, 2023Common StockSSaleDisposed−1,237$802.54F5−$992,741.98198,891Indirect
Mar 23, 2023Common StockSSaleDisposed−642$803.30F6−$515,718.6198,249Indirect
Mar 23, 2023Common StockSSaleDisposed−254$804.38F7−$204,312.52197,995Indirect
Mar 23, 2023Common StockSSaleDisposed−47$805.55−$37,860.85197,948Indirect
Mar 23, 2023Common StockSSaleDisposed−700$806.47−$564,529197,248Indirect
Mar 23, 2023Common StockSSaleDisposed−400$810.30−$324,120196,848Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents volume-weighted average price of sales of 254 shares of Company stock on March 23, 2023 at prices ranging from $800.52 to $800.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

Represents volume-weighted average price of sales of 122 shares of Company stock on March 23, 2023 at prices ranging from $801.00 to $801.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.

Referenced by the price of 1 transaction in Table I.

F5

Represents volume-weighted average price of sales of 1,237 shares of Company stock on March 23, 2023 at prices ranging from $802.00 to $802.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.

Referenced by the price of 1 transaction in Table I.

F6

Represents volume-weighted average price of sales of 642 shares of Company stock on March 23, 2023 at prices ranging from $803.01 to $803.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.

Referenced by the price of 1 transaction in Table I.

F7

Represents volume-weighted average price of sales of 254 shares of Company stock on March 23, 2023 at prices ranging from $804.00 to $804.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)